Evidence map›Paper›PMID 39131369›Full record

ArticlebioRxiv : the preprint server for biology2024

Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in Systemic Lupus Erythematosus.

Minji Ai, Xian Zhou, Michele Carrer, Paymaan Jafar-Nejad, Yanfeng Li, Naomi Gades, Mariam Alexander, Mario A Bautista, Ali A Duarte Garcia, Hu Zeng

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Minji AiDivision of Rheumatology, Department of Medicine, Mayo Clinic Rochester, MN, USA.
Xian ZhouDivision of Rheumatology, Department of Medicine, Mayo Clinic Rochester, MN, USA.
Michele CarrerIonis Pharmaceuticals, Carlsbad, CA, USA.
Paymaan Jafar-NejadIonis Pharmaceuticals, Carlsbad, CA, USA.
Yanfeng LiDivision of Rheumatology, Department of Medicine, Mayo Clinic Rochester, MN, USA.
Naomi GadesDepartment of Comparative Medicine, Mayo Clinic Arizona, USA.
Mariam AlexanderDivision of Laboratory Medicine and Pathology, Mayo Clinic Rochester, MN, USA.ORCID 0000-0001-9072-9871
Mario A BautistaDivision of Rheumatology, Department of Medicine, Mayo Clinic Rochester, MN, USA.
Ali A Duarte GarciaDivision of Rheumatology, Department of Medicine, Mayo Clinic Rochester, MN, USA.
Hu ZengDivision of Rheumatology, Department of Medicine, Mayo Clinic Rochester, MN, USA.ORCID 0000-0002-9909-7732

Funding

Context dependent amino acid availability and sensing determines humoral immunityR01AI162678 · NIAID · MAYO CLINIC ROCHESTER · PI Hu Zeng · 2022 to 2026
$2.3M
Immune Checkpoint Inhibition and humoral immune response in systemic autoimmunityR01AR077518 · NIAMS · MAYO CLINIC ROCHESTER · PI ZENG, HU · 2021 to 2025
$1.7M
NIAID NIH HHS R01 AI162678NIAMS NIH HHS R01 AR077518
6 · The paper itself

Abstract

Objective: We aim to explore the role of mechanistic target of rapamycin complex (mTORC) 2 in systemic lupus erythematosus (SLE) development, the in Method: We first induced lupus-like disease in T cell specific Results: T cell specific Conclusion: Targeting mTORC2 could be a promising therapeutic for SLE.

Indexed as

antisense oligonucleotideimmunopathologymTORC2Systemic lupus erythematosus

Identifiers

PMID39131369
PMCPMC11312597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.